Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Back to filter
Show all topics (10)
Related topics
Educational webinar: Introducing MARS Platform for gentle cell separation
Sep 6, 2023
Join us for a webinar where we will introduce the new MARS Platform by Applied Cells, a...
Aug 17, 2023
Register for an engaging webinar led by Naz Chaudary, Ph.D., and Research Technician, Alex Wang from the...
Optimizing Gene Expression with Bioluminescence & the piggyBac System
Aug 15, 2023
Discover how bioluminescence imaging & the piggyBac gene editing system optimize & track gene expression in mouse...
High-plex immunofluorescence imaging and traditional histology of the same tissue section
Aug 7, 2023
RareCyte Orion’ platform has been used for collecting H&E and high-plex immunofluorescence images from the same cells...
Drive key insights and discoveries with NEW Live Cell Analysis applications for eSight system
Aug 2, 2023
eSight is now powerful like never before. Learn more about new dedicated application modules for live-cell analysis: 3D...
Single cell-resolution in situ sequencing elucidates spatial dynamics of multiple sclerosis
Jul 14, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, fluidics, image processing,...
MARS - High Efficiency Separation of CD34+ HSC from Mobilized Blood
Jul 12, 2023
MARS platform provides an easy and cost-effective protocol for CD34+ cell isolation. Single pass CD34+ HSC enrichment...
43 markers, ONE tube : Impress yourself with Cytek Aurora Spectral Cytometer
Jul 11, 2023
Using Cytek full spectrum flow cytometry, scientists at Hamad Medical Corporation, developed a 43 color panel to...
InAlyzer - The technology chosen by NASA
Jul 10, 2023
MEDIKORS's InAlyzer was finally selected as the equipment to be used for NASA's space environment biological research
Nature Article: The genomic landscape of pediatric acute lymphoblastic leukemia
Jun 29, 2023
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using whole-genome, exome and...
Red-shifted firefly luciferase optimized for Candida albicans in vivo bioluminescence imaging
Sep 15, 2017
The authors of this study attempted to compare the performance of BLI in the present study with that published using the systemic infection model and light detection in the region of the kidneys. They estimated that a lower limit of detection for BLI (50 photon/s/mm2) corresponded to of about 200 CFU/kidney with the instrumentation used here (in-vivo Xtreme II). Given numbers published by Jacobsen et al. (2014) (100 photon/s/mm2 for 3,600 CFU/kidney), this suggests that the method used here increases at least by 4- to 8-fold the sensitivity of C. albicans detection.
This performance can be attributed to several factors including (i) the type of luciferase used (Mut2 has better tissue penetration capacities than the wild type luciferase) and (ii) technical differences provided by the luminescence acquisition of instruments. This performance is even more remarkable when taking in account that BLI data was collected here from animals contained in Sealed Optical Imaging Trays, which may create another obstacle of emitted light to the high sensitivity camera.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Brand profile
